Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple drink protect your eyesight?

NCT ID NCT06333236

Disease control Sponsor: ASST Santi Paolo e Carlo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a daily oral solution containing citicoline and nicotinamide (Kron) could improve eye function in 30 people with open-angle glaucoma. Participants took the supplement and had their retinal and visual cortex activity measured. The goal was to see if the combination could offer short-term benefits for vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
citicoline and nicotinamide oral solution
What this could lead to
If it works, this could point toward a nutritional supplement that helps protect vision in people with glaucoma.
What could go wrong
This was a very small, early study with only 30 participants and no control group, so results may not be reliable or apply to everyone. It also does not address the root cause of glaucoma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Apr 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * glaucomatous patients with moderate visual field loss, MD ranging from -6 dB and -12 dB, and risk of progression * controlled intraocular pressure * at least 3 previous visual field examinations. Exclusion Criteria: * angle closure glaucoma and secondary open angle glaucoma * refractive error outside +2D and -6D * ophthalmic surgery 6 months before the recruitment * presence of cataract or other conditions that could affect results of perimetry or electroretinography * treatment with supplements in any form with a demonstrated or presumed neuroprotecting/neuroenhancing effect in the last six months * presence of other ocular or systemic diseases that could affect results of perimetry or electroretinography.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

Contacts and locations

Locations

  • ASST Santi Paolo e Carlo

    Milan, Mi, 20142, Italy

  • Luca Rossetti

    Milan, MI, 20142, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.